Ruti Aga: Six Years, and a Prescription No Clinic Ever Wrote

A March morning, a World Athletics label half marathon in China, an elite women's field, and Ruti Aga crossing first. There is no split from that race in front of me. No official timing release, no field-depth breakdown — only a win and a name. Fifteen years of calling road races and Diamond Leagues off studio monitors have taught me to hear one thing first in a closed room: those three seconds after the noise dies and before the mic goes down. I learned the crowd's silence before I learned its roar.

On Thursday the Athletics Integrity Unit (AIU) statement landed. A six-year ban. And inside it, one sentence that belongs less in a sports report than in a case file: the methylprednisolone prescription was written by a family member who was not a doctor; it was written on an "old prescription pad from a former workplace"; and the clinic named on the document did not exist. Thirty-two years old. Six years.

The substance matters more than the headlines allowed. Methylprednisolone is a glucocorticoid, WADA Prohibited List class S9 — not an anabolic steroid, which is S1. Under the current List, S9 substances are prohibited in-competition only, and only by injection, oral or rectal routes. A therapeutic knee injection given out of competition is entirely lawful. It becomes a violation when residues are present in-competition — and a road race's testing window opens at 23:59 the day before the start, which is why an injection given days earlier gets caught.

Several reports described the substance as a "prohibited steroid." That is technically wrong, and it is not a small wording problem: it moves the hinge of the entire case. Because S9 applies only in-competition, Aga's defence lay not in the existence of the drug but in its route and timing. With genuine medical records, the case might never have existed.

There is a system change almost nobody noticed: the 2026 revision of the Prohibited List turned in-competition glucocorticoid injection into a strict violation. The patch notes arrived before the players did — and they certainly never reached the entourages.

Aga's record predates the ban and cannot be erased: the 2026 Tokyo Marathon title, three World Marathon Majors runner-up finishes. The roughly 2:18:34 from Berlin 2026 comes from external recall, not from the AIU statement. That is the record of a genuinely elite marathoner, and it is the part of this story the sanction headline buried.

Now the arithmetic. Two years for the presence violation, four years for tampering — six total. Four years is the Code's standard tampering sanction, so the sum is not unusual in itself. What is unusual is what the sum reveals: the panel rejected the no-significant-fault mitigation that would have cut the presence sanction, and treated the tampering as fully culpable. That, not the substance, is where the six years came from.

The tampering charge carries a second signal the headlines missed: it rests not on paper alone but on statements made in interview. What was said under AIU questioning became part of the sanction. Language and translation conditions in AIU interviews with Ethiopian athletes have been a recurring point of friction; the debate is not recorded here, but the room for it is.

The root cause sits in a knee. The statement attributes the methylprednisolone to a knee injury, and intra-articular injection for knee synovitis is standard sports medicine in distance runners. That clinical plausibility is exactly what makes the forgery so destructive. Real treatment would have been defended with real records. Instead the one defence that could have worked was destroyed by the athlete's own hand.

A syringe in Gold Coast taught me that recovery is a public performance. In 2026 I was in the host chair when Neeraj Chopra won Commonwealth javelin gold, and within days a syringe found in the team village turned my broadcast into a corridor of denials, paperwork and half-answers. I started a two-column notebook after that — what broke on the left, who runs next on the right. Aga's case belongs in the left column.

The medical support picture is stark: there was none. The "doctor" was an unregistered family member who claimed an old prescription pad from a former workplace, which the clinic flatly disowned. Three independent verification failures on one sheet of paper. That is not a filing error; it is the signature of an athlete operating without a credentialed team physician.

The second absence is the TUE. A properly managed athlete either holds or applies for a therapeutic use exemption, or observes the WADA route-specific washout period after an injection. Neither happened here — and the proof of that is that a document was forged instead.

This is where the appearance-fee economy and the testing economy collide. China's label-race circuit has been a high-start-fee, low-risk income tier for East African marathoners, the cash flow between Majors for a 2:18–2:20 athlete. It is now also the AIU's highest-yield testing ground. Both economies run through the same races, and the athlete stands between them.

The disqualification scope is unstated, but standard AIU practice voids the result and prize money from the competition where the sample was collected. So the March win, whose splits were never published, comes off the record too. Earlier results — Tokyo 2026 included — are not automatically annulled, because the violation is anchored to a later date; the statement announces no retrospective erasure.

The ban runs from 10 September, the same date as the provisional suspension, and provisional time counts against the sanction. That is procedural bookkeeping, not relief. At thirty-two, six years means a return at roughly 38, and in the depth of Ethiopian women's marathon running, a 38-year-old with a doping record is effectively unselectable. The ban is six years on paper; professionally it is a lifetime.

The larger shift this case records sits at the border between detection and documentation. The enforcement frontier has moved from "was the substance there" to "does this piece of paper exist." On the day an agency picks up the phone to the clinic, an old prescription pad is worth nothing.

Here is where I stop myself. Six years draws an instinctive reaction: that much for a glucocorticoid? Technically the reaction is not wrong — methylprednisolone has no proven endurance benefit. But the sanction did not come from the substance; it came from the document. An athlete who could produce real records faced two years at worst. One who forged a prescription faced six.

The real disproportion sits upstream. An athlete with a credentialed team physician and TUE infrastructure never has this case at all — a knee injection, correct timing, clean paperwork, no proceedings. An athlete without that structure is left with an old pad and a relative. The penalty is recording a gap in medical support and writing it onto the athlete's character.

A second caution: do not erase the 2026 Tokyo title, and do not upgrade it into a moral medal. It is a result, and it stands unless earlier use is proven. Nor does "she won, so she was doping" survive scrutiny — a glucocorticoid is not an endurance drug, and winning is not evidence of benefit. The headline that called it a steroid turned an administrative failure into a morality play, and morality plays have never produced better medical support.

A host is just a translator between the scoreboard and the story. The translation here is plain: a 32-year-old, a knee injury, a relative, a forged prescription, six years. The questions that remain point forward. Who advised the forgery? Was the agent or management investigated, or does the statement name only the family member? How many cases sit in the same training clusters, served by the same informal medical network? The appeal window — roughly 21 days from the reasoned decision — is open, but a document-based finding is close to unappealable.

So I keep the right-hand column of the notebook open. On the left, six years. On the right, the next morning, when another runner's knee gives out and there is no credentialed doctor to ask. The question is which reaches her first — the agency, or the old prescription pad.